Adolescents between the ages of 13-16 with a first degree relative (full-sibling or biological parent) diagnosed with schizophrenia, schizoaffective or schizophreniform disorder are invited to participate in a research study investigating brain connectivity and development in teens conducted at the UI Department of Psychiatry. The study includes 2 MRI scans and requires 3 visits to the University of Iowa Hospitals and Clinics and 4 follow-up phone calls over a 3-year period. Compensation is available. For more information, call Julie at (319) 384-6521 or email@example.com or toll free 1-866-890-5972.
Participants in this study have recently been diagnosed with a type of leukemia (blood cancer) called chronic myelogenous leukemia (CML). The purpose of this study is to evaluate ponatinib as a potential treatment for patients who have been newly diagnosed with CML. Ponatinib is an experimental anti-cancer drug. This study will compare the effects of ponatinib to another drug called imatinib. Imatinib is approved by the United States Food and Drug Administration (FDA) for treating a variety of human cancers including newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. This study will enroll approximately 530 participants (subjects) in about 175 centers worldwide.
Karen Parrott, 319-353-6347
Participants in this research study have been diagnosed with a tumor such as carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells with special proteins called somatostatin receptors. The purpose of this research study is to see if the tumors can be identified using a special procedure called a positron emission tomography (PET) scan and see if it is as effective as having an Octreoscan and a diagnostic CT. Participants will have an injection with a radioactive drug called 68Gallium-DOTA-tyr3-Octreotide (68Ga-DOTATOC) that binds to tumor cells that have somatostatin receptors and then have a PET scan. A "low dose" computed tomography (CT) scan will then be done on the same scanner. 68Ga-DOTATOC is considered investigational, which means that it has not yet been approved by the U.S. Food and Drug Administration (FDA). The FDA has granted permission to conduct this study under an investigator's new drug (IND) application. About 112 people will take part in this study conducted by investigators at the University of Iowa.
Mary Schall, 319-356-3516
Participants in this research sub-study must initially take part in the main research study "Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma." The purpose of the substudy is to find out more about what causes disease and the differences in the way people respond to drug therapies. The study consists of providing blood samples, additional biological samples such as left over tumor biopsy or archival tumor tissue samples collected during the main study.
Melanie Frees, 319-356-1228
Copyright © 2013 The University of Iowa. All Rights Reserved.